Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Autor: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group

Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314